Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Marin Oyarzún, Cecilia P ^a   Carestia, Agostina ^b   Lev, Paola R ^a   Glembotsky, Ana C ^a   Castro Ríos, Miguel A ^c   Moiraghi, Beatriz ^d   Molinas, Felisa C ^a   Marta, Rosana F ^a   Schattner, Mirta ^b   Heller, Paula G ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Universidad Nacional de Río Cuarto Consejo Nacional de Investigaciones Científicas y Técnicas   (Argentina)

^c Consultorios Hematológicos ^*  (Argentina)

^d HOSPITAL RAMOS MEJÍA   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

PEROXIDASE; REACTIVE OXYGEN METABOLITE; TUMOR MARKER;

ADULT; AGED; BLOOD; CHRONIC DISEASE; CLINICAL TRIAL; EXTRACELLULAR TRAP; FEMALE; HEMATOLOGIC DISEASE; HUMAN; MALE; METABOLISM; MIDDLE AGED; MYELOPROLIFERATIVE DISORDER; NEUTROPHIL; NUCLEOSOME; PATHOLOGY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; CHRONIC DISEASE; EXTRACELLULAR TRAPS; FEMALE; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; NEUTROPHILS; NUCLEOSOMES; PEROXIDASE; REACTIVE OXYGEN SPECIES;

EID: 85005992614     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep38738     Document Type: Article

References (54)

1. Tefferi, A. & Pardanani, A. Myeloproliferative neoplasms: a contemporary review. JAMA Oncol. 1, 97-105 (2015).
2. Barbui, T., Finazzi, G. & Falanga, A. Myeloproliferative neoplasms and thrombosis. Blood 122, 2176-2184 (2013).
3. Barbui, T. et al. Disease characteristics and clinical outcome in young adults with essential hrombocythemia versus early/prefibrotic primary myelofibrosis. Blood 120, 569-571 (2012).
4. Carobbio, A. et al. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 109, 2310-2313 (2007).
5. Falanga, A. et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 96, 4261-4266 (2000).
6. Arellano-Rodrigo, E. et al. Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status. Haematologica 91, 169-175 (2006).
7. Goette, N. P. et al. Monocyte IL-2Ralpha expression is associated with thrombosis and the JAK2V617F mutation in myeloproliferative neoplasms. Cytokine 51, 67-72 (2010).
8. Tefferi, A. et al. Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol 29, 1356-1363 (2011).
9. Falanga, A. & Marchetti, M. Thrombotic disease in the myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program 2012, 571-581 (2012).
10. Brinkmann, V. et al. Neutrophil extracellular traps kill bacteria. Science 303, 1532-1535 (2004).
11. Fuchs, T. A. et al. Novel cell death program leads to neutrophil extracellular traps. J Cell Biol 176, 231-241 (2007).
12. Keshari, R. S. et al. Cytokines induced neutrophil extracellular traps formation: implication for the inflammatory disease condition. PLoS One 7, e48111 (2012).
13. Caudrillier, A. et al. Platelets induce neutrophil extracellular traps in transfusion-related acute lung injury. J Clin Invest 122, 2661-2671 (2012).
14. Carestia, A. et al. Mediators and molecular pathways involved in the regulation of neutrophil extracellular trap formation mediated by activated platelets. J Leukoc Biol 99, 153-162 (2016).
15. Kessenbrock, K. et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med; 15, 623-625 (2009).
16. Fuchs, T. A. et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci USA 107, 15880-15885 (2010).
17. Martinod, K. & Wagner, D. D. Thrombosis: tangled up in NETs. Blood 123, 2768-2776 (2014).
18. Engelmann, B. & Massberg, S. Thrombosis as an intravascular effector of innate immunity. Nat Rev Immunol 13, 34-45 (2013).
19. Brill, A. et al. Neutrophil extracellular traps promote deep vein thrombosis in mice. J Thromb Haemost 10, 136-144 (2012).
20. Savchenko, A. S. et al. VWF-mediated leukocyte recruitment with chromatin decondensation by PAD4 increases myocardial ischemia/reperfusion injury in mice. Blood 123, 141-148 (2014).
21. Savchenko, A. S. et al. Neutrophil extracellular traps form predominantly during the organizing stage of human venous thromboembolism development. J Thromb Haemost 12, 860-870 (2014).
22. de Boer, O. J. et al. Neutrophils, neutrophil extracellular traps and interleukin-17 associate with the organisation of thrombi in acute myocardial infarction. Thromb Haemost 109, 290-297 (2013).
23. van Montfoort, M. L. et al. Circulating nucleosomes and neutrophil activation as risk factors for deep vein thrombosis. Arterioscler Thromb Vasc Biol 33, 147-151 (2013).
24. Hirose, T. et al. Presence of neutrophil extracellular traps and citrullinated histone H3 in the bloodstream of critically ill patients. PLoS One 9, e111755 (2014).
25. Wong, S. L. et al. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing. Nat Med 21, 815-819 (2015).
26. Demers, M. et al. Cancers predispose neutrophils to release extracellular DNA traps that contribute to cancer-associated thrombosis. Proc Natl Acad Sci USA 109, 13076-13081 (2012).
27. Maugeri, N. et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 4, 2593-2598 (2006).
28. Lapponi, M. J. et al. Regulation of neutrophil extracellular trap formation by anti-inflammatory drugs. J Pharmacol Exp Ther 345, 430-437 (2013).
29. Hurtado-Nedelec, M. et al. Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation. Haematologica 98, 1517-1524 (2013).
30. Vaidya, R. et al. Plasma cytokines in polycythemia vera: phenotypic correlates, prognostic relevance, and comparison with myelofibrosis. Am J Hematol 87, 1003-1005 (2012).
31. Sur Chowdhury, C. et al. Enhanced neutrophil extracellular trap generation in rheumatoid arthritis: analysis of underlying signal transduction pathways and potential diagnostic utility. Arthritis Res Ther. 16, R122 (2014).
32. Hashiba, M. et al. Neutrophil extracellular traps in patients with sepsis. J Surg Res 194, 248-254 (2015).
33. Etulain, J. et al. P-selectin promotes neutrophil extracellular trap formation in mice. Blood 126, 242-246 (2015).
34. Hakkim, A. et al. Activation of the Raf-MEK-ERK pathway is required for neutrophil extracellular trap formation. Nat Chem Biol 7, 75-77 (2011).
35. Gangat, N. et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 29, 392-397 (2011).
36. Borissoff, J. I. et al. Elevated levels of circulating DNA and chromatin are independently associated with severe coronary atherosclerosis and a prothrombotic state. Arterioscler Thromb Vasc Biol 33, 2032-2040 (2013).
37. Marty, C. et al. A role for reactive oxygen species in JAK2V617F myeloproliferative neoplasm progression. Leukemia 27, 2187-2195 (2013).
38. Kagoya, Y. et al. JAK2V617F+ myeloproliferative neoplasm clones evoke paracrine DNA damage to adjacent normal cells through secretion of lipocalin-2. Blood 124, 2996-3006 (2014).
39. Rampal, R. et al. Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood 123, e123-133 (2014).
40. Remijsen, Q. et al. Neutrophil extracellular trap cell death requires both autophagy and superoxide generation. Cell Res 21, 290-304 (2011).
41. Wolach, B., Gavrieli, R., Manor, Y. & Lishner, M. Leukocyte function in chronic myeloproliferative disorders. Blood Cells Mol Dis 24, 544-551 (1998).
42. Chen, R., Kang, R., Fan, X. G. & Tang, D. Release and activity of histone in diseases. Cell Death Dis 5, e1370 (2014).
43. Holdenrieder, S. et al. Nucleosomes in serum of patients with benign and malignant diseases. Int J Cancer 95, 114-120 (2001).
44. Gould, T. J., Lysov, Z. & Liaw, P. C. Extracellular DNA and histones: double-edged swords in immunothrombosis. J Thromb Haemost 13, Suppl 1 S82-91 (2015).
45. Alhamdi, Y. & Toh, C. H. The role of extracellular histones in haematological disorders. Br J Haematol 173, 805-811 (2016).
46. Allam, R. et al. Histones from dying renal cells aggravate kidney injury via TLR2 and TLR4. J Am Soc Nephrol 23, 1375-1388 (2012).
47. Verstovsek, S. et al. Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363, 1117-1127 (2010).
48. Vardiman, J. W. et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 114, 937-951 (2009).
49. Thomas, G. M. et al. Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. Blood 119, 6335-6343 (2012).
50. Fuchs, T. A. et al. Neutrophils release extracellular DNA traps during storage of red blood cell units. Transfusion 53, 3210-3216 (2013).
51. Etulain, J. et al. Acidosis downregulates platelet haemostatic functions and promotes neutrophil proinflammatory responses mediated by platelets. Thromb Haemost 107, 99-110 (2012).
52. Heller, P. G. et al. JAK2V617F mutation in platelets from essential thrombocythemia patients: correlation with clinical features and analysis of STAT5 phosphorylation status. Eur J Haematol 77, 210-216 (2006).
53. Glembotsky, A. C. et al. Screening for MPL mutations in essential thrombocythemia and primary myelofibrosis: normal Mpl expression and absence of constitutive STAT3 and STAT5 activation in MPLW515L-positive platelets. Eur J Haematol 84, 398-405 (2010).
54. Mela Osorio, M. J. et al. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status. Eur J Haematol 96, 435-442 (2016).